Modifying disability in progressive multiple sclerosis

First Page		Document Content
Brain Immune system Immunosuppressants Carbamates Darunavir Sulfonamides Glatiramer acetate Laquinimod Antiretroviral drug Multiple sclerosis Protease inhibitors Immunology		Modifying disability in progressive multiple sclerosis Add to Reading List Source URL: download.thelancet.com Download Document from Source Website File Size: 203,46 KB Share Document on Facebook

	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULYZAQ safely and effectively. See full prescribing information for FULYZAQ. FULYZAQ ® (crofelemer) delayed-releas DocID: 1gtlL - View Document
	SUPPLEMENT ARTICLE Drug-Drug Interactions in the Treatment of HCV Among People Who Inject Drugs Stefan Mauss1 and Hartwig Klinker2 1 DocID: 1giaR - View Document
	AIDS Research and Therapy BioMed Central Research DocID: 1aNo3 - View Document
	MS&D logo_no qualifier_2 lines DocID: 1a8lZ - View Document
	Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I DocID: 1a178 - View Document